Loading clinical trials...

Dapagliflozin DPPIV Inhibitor add-on Study | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Dapagliflozin DPPIV Inhibitor add-on Study

A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin

NCT00984867•AstraZeneca

View on ClinicalTrials.gov

Summary

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with type 2 diabetes
•Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these
•Patients will be screened by a blood test and only those who need additional therapy can be enrolled

Exclusion Criteria

•Patients with type 1 diabetes
•Patients with very poorly controlled diabetes
•Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study

Locations (88)

Research Site

Huntsville, Alabama, United States

Research Site

Ozark, Alabama, United States

Research Site

Anaheim, California, United States

Research Site

Chula Vista, California, United States

Research Site

Greenbrae, California, United States

Research Site

Laguna Hills, California, United States

Research Site

Los Angeles, California, United States

Research Site

Riverside, California, United States

Research Site

West Hills, California, United States

Research Site

Boca Raton, Florida, United States

Key Dates

Start Date

October 1, 2009

Primary Completion Date

March 1, 2011

Completion Date

September 1, 2011

Last Updated

June 13, 2014

Enrollment

833

ACTUAL participants

Conditions

Type 2 Diabetes

Interventions

Dapagliflozin

DRUG

Placebo

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dapagliflozin DPPIV Inhibitor add-on Study

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D

Closed-loop in Adults With Type 2 Diabetes